Journal Mobile Options
Table of Contents
Vol. 13, No. 6, 2008
Issue release date: October 2008
Section title: Original Paper
Audiol Neurotol 2008;13:388–395
(DOI:10.1159/000148202)

Spiral Ganglion Outgrowth and Hearing Development in p75NTR-Deficient Mice

Brors D.a · Hansen S.a · Mlynski R.b · Volkenstein S.a · Aletsee C.b · Sendtner M.c · Ryan A.F.d · Dazert S.a
aDepartment of Otolaryngology, Head and Neck Surgery, Ruhr-University Bochum, Bochum, and Departments of bOtolaryngology, Head and Neck Surgery, and cNeurobiology, Bayerische Julius-Maximilians-University, Würzburg, Germany; dDepartment of Otolaryngology, University of California, San Diego, Calif., USA

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.



Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: 3/21/2007
Accepted: 4/9/2008
Published online: 7/29/2008
Issue release date: October 2008

Number of Print Pages: 8
Number of Figures: 3
Number of Tables: 2

ISSN: 1420-3030 (Print)
eISSN: 1421-9700 (Online)

For additional information: http://www.karger.com/AUD

Abstract

To explore the role of nerve growth factor receptor p75NTR during the terminal neuronal development of the mammalian cochlea the onset of hearing and the in vitro response of spiral ganglion neurites to neurotrophin 3 (NT-3), which is known to play a critical role during neonatal inner ear development, were investigated in p75NTR-deficient mice (p75NTR–/–). Auditory-evoked brain stem response recordings from p75NTR–/– and wild-type (WT) littermates were measured from postnatal days (PD) 8 to 23. Additionally, spiral ganglion explants from p75NTR–/– and WT animals were dissected and cultured in an organotypic tissue culture system. In both groups, spiral ganglion neurite outgrowth was analyzed with and without NT-3 supplementation. No significant differences in the onset of hearing of mutant mice compared to the WT mice were detected, and both groups showed a similar development of hearing until PD 23. After stimulation with NT-3, neurite outgrowth was enhanced in both p75NTR–/– and WT mice. However, neurites from p75NTR–/– spiral ganglion explants were longer in both culture conditions. Moreover, NT-3 did not significantly enhance neurite number in p75NTR–/–, as it did in WT mice. P75NTR has a remarkable influence on spiral ganglion neurite growth behavior. However, p75NTR does not seem to be essential for the development of basic hearing function in the first 3 postnatal weeks.

© 2008 S. Karger AG, Basel


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: 3/21/2007
Accepted: 4/9/2008
Published online: 7/29/2008
Issue release date: October 2008

Number of Print Pages: 8
Number of Figures: 3
Number of Tables: 2

ISSN: 1420-3030 (Print)
eISSN: 1421-9700 (Online)

For additional information: http://www.karger.com/AUD


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.